Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q2 EPS of ($0.41), $0.02 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $733.33 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.